APA (7th ed.) Citation

Subbiah, V., Wolf, J., Konda, B., Kang, H., Spira, A., Weiss, J., . . . Drilon, A. (2022). Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): A phase 1/2, open-label, basket trial. The lancet oncology, 23(10), 1261-1273. https://doi.org/10.1016/S1470-2045(22)00541-1

Chicago Style (17th ed.) Citation

Subbiah, Vivek, et al. "Tumour-agnostic Efficacy and Safety of Selpercatinib in Patients with RET Fusion-positive Solid Tumours Other than Lung or Thyroid Tumours (LIBRETTO-001): A Phase 1/2, Open-label, Basket Trial." The Lancet Oncology 23, no. 10 (2022): 1261-1273. https://doi.org/10.1016/S1470-2045(22)00541-1.

MLA (9th ed.) Citation

Subbiah, Vivek, et al. "Tumour-agnostic Efficacy and Safety of Selpercatinib in Patients with RET Fusion-positive Solid Tumours Other than Lung or Thyroid Tumours (LIBRETTO-001): A Phase 1/2, Open-label, Basket Trial." The Lancet Oncology, vol. 23, no. 10, 2022, pp. 1261-1273, https://doi.org/10.1016/S1470-2045(22)00541-1.